Nathan A. Pennell, MD, PhD

Among other things, Pennell focused on data regarding atezolizumab as adjuvant therapy to improve disease-free survival for patients with stage II/III resected non–small cell lung cancer.

Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC.

Bronchioloalveolar carcinoma (BAC) is a unique subtype of lung adenocarcinoma that has received increasing attention in recent years. Levy and colleagues have provided a comprehensive review of the clinical and pathologic characteristics of this disease, as well as the clinical evidence available to guide treatment of patients with BAC.